CO2017007679A2 - Derivatives of 1- (het) arylsulfonyl- (pyrrolidine or piperidine) -2-carboxamide and their use as trpa1 antagonists - Google Patents
Derivatives of 1- (het) arylsulfonyl- (pyrrolidine or piperidine) -2-carboxamide and their use as trpa1 antagonistsInfo
- Publication number
- CO2017007679A2 CO2017007679A2 CONC2017/0007679A CO2017007679A CO2017007679A2 CO 2017007679 A2 CO2017007679 A2 CO 2017007679A2 CO 2017007679 A CO2017007679 A CO 2017007679A CO 2017007679 A2 CO2017007679 A2 CO 2017007679A2
- Authority
- CO
- Colombia
- Prior art keywords
- compounds
- arylsulfonyl
- het
- carboxamide
- pyrrolidine
- Prior art date
Links
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 title 3
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 title 2
- 101100482465 Caenorhabditis elegans trpa-1 gene Proteins 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 5
- 238000000034 method Methods 0.000 abstract 2
- 101000764872 Homo sapiens Transient receptor potential cation channel subfamily A member 1 Proteins 0.000 abstract 1
- 102100026186 Transient receptor potential cation channel subfamily A member 1 Human genes 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6509—Six-membered rings
- C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La invención se refiere a compuestos de fórmula I y sales de los mismos y otros compuestos de fórmulas II-IX tal como se divulgan en el presente documento. Además, la presente invención se refiere a métodos para fabricar y a métodos para usar los compuestos de fórmulas I-IX así como a composiciones farmacéuticas que contienen dichos compuestos. Los compuestos pueden ser útiles para tratar enfermedades y afecciones mediadas por TRPA1, tales como dolor o asma.The invention relates to compounds of formula I and salts thereof and other compounds of formulas II-IX as disclosed herein. Furthermore, the present invention relates to methods for manufacturing and to methods for using the compounds of formulas I-IX as well as pharmaceutical compositions containing said compounds. The compounds may be useful for treating TRPA1-mediated diseases and conditions, such as pain or asthma.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2015073102 | 2015-02-15 | ||
CN2015076318 | 2015-04-10 | ||
CN2016071061 | 2016-01-15 | ||
PCT/EP2016/052950 WO2016128529A1 (en) | 2015-02-15 | 2016-02-12 | 1-(het)arylsulfonyl-(pyrrolidine or piperidine)-2-carboxamide derivatives and their use as trpa1 antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2017007679A2 true CO2017007679A2 (en) | 2017-10-20 |
Family
ID=55349845
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2017/0007679A CO2017007679A2 (en) | 2015-02-15 | 2017-07-28 | Derivatives of 1- (het) arylsulfonyl- (pyrrolidine or piperidine) -2-carboxamide and their use as trpa1 antagonists |
Country Status (21)
Country | Link |
---|---|
US (1) | US10179782B2 (en) |
EP (1) | EP3256463B1 (en) |
JP (1) | JP6700291B2 (en) |
KR (1) | KR20170118166A (en) |
CN (1) | CN107922392B (en) |
AU (1) | AU2016217851A1 (en) |
BR (1) | BR112017017052A2 (en) |
CA (1) | CA2975196A1 (en) |
CL (1) | CL2017001987A1 (en) |
CO (1) | CO2017007679A2 (en) |
CR (1) | CR20170367A (en) |
EA (1) | EA033497B1 (en) |
HK (1) | HK1251815A1 (en) |
IL (1) | IL253478A0 (en) |
MX (1) | MX2017010300A (en) |
PE (1) | PE20180177A1 (en) |
PH (1) | PH12017501478A1 (en) |
PT (1) | PT3256463T (en) |
SG (1) | SG11201706451TA (en) |
TW (1) | TW201639829A (en) |
WO (1) | WO2016128529A1 (en) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI633087B (en) | 2012-06-13 | 2018-08-21 | 赫孚孟拉羅股份公司 | New diazaspirocycloalkane and azaspirocycloalkane |
WO2014048865A1 (en) | 2012-09-25 | 2014-04-03 | F. Hoffmann-La Roche Ag | New bicyclic derivatives |
AR095079A1 (en) | 2013-03-12 | 2015-09-16 | Hoffmann La Roche | DERIVATIVES OF OCTAHIDRO-PIRROLO [3,4-C] -PIRROL AND PIRIDINA-FENILO |
JP6496730B2 (en) | 2013-11-26 | 2019-04-03 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Novel octahydro-cyclobuta [1,2-c; 3,4-c '] dipyrrol-2-yl |
AU2015238541B2 (en) | 2014-03-26 | 2019-09-19 | F. Hoffmann-La Roche Ag | Condensed [1,4]diazepine compounds as autotaxin (ATX) and lysophosphatidic acid (LPA) production inhibitors |
MA50635A (en) | 2014-03-26 | 2020-08-12 | Hoffmann La Roche | NEW BICYCLIC COMPOUNDS AS INHIBITORS OF AUTOTAXIN (ATX) AND LYSOPHOSPHATIDIC ACID PRODUCTION |
TWI676626B (en) * | 2014-04-23 | 2019-11-11 | 美商美國禮來大藥廠 | Inhibiting the transient receptor potential a1 ion channel |
SG11201702817SA (en) | 2014-10-06 | 2017-05-30 | Vertex Pharma | Modulators of cystic fibrosis transmembrane conductance regulator |
JP6800872B2 (en) | 2015-03-06 | 2020-12-16 | ファーマケア,インク. | Lysyl oxidase-like 2 inhibitor and its use |
SG11201707246YA (en) * | 2015-03-06 | 2017-10-30 | Pharmakea Inc | Fluorinated lysyl oxidase-like 2 inhibitors and uses thereof |
MA41898A (en) | 2015-04-10 | 2018-02-13 | Hoffmann La Roche | BICYCLIC QUINAZOLINONE DERIVATIVES |
US20180186755A1 (en) * | 2015-07-01 | 2018-07-05 | Pharmakea, Inc. | Lysyl oxidase-like 2 inhibitors and uses thereof |
EP3344619B1 (en) | 2015-09-04 | 2020-10-28 | H. Hoffnabb-La Roche Ag | Phenoxymethyl derivatives |
RU2018112230A (en) | 2015-09-24 | 2019-10-30 | Ф. Хоффманн-Ля Рош Аг | BICYCLE COMPOUNDS AS ATX INHIBITORS |
WO2017050791A1 (en) | 2015-09-24 | 2017-03-30 | F. Hoffmann-La Roche Ag | New bicyclic compounds as dual atx/ca inhibitors |
MX2017015034A (en) | 2015-09-24 | 2018-04-13 | Hoffmann La Roche | New bicyclic compounds as dual atx/ca inhibitors. |
CA2983782A1 (en) | 2015-09-24 | 2017-03-30 | F. Hoffmann-La Roche Ag | Bicyclic compounds as atx inhibitors |
CN108602807B (en) * | 2016-02-05 | 2022-05-13 | Ea制药株式会社 | Heterocyclic sulfonamide derivatives and drugs containing the same |
WO2018015410A1 (en) * | 2016-07-20 | 2018-01-25 | F. Hoffmann-La Roche Ag | Bicyclic proline compounds |
CN109476628B (en) | 2016-07-20 | 2022-01-11 | 豪夫迈·罗氏有限公司 | Sulfonylcycloalkylamide compounds as TRPA1 modulators |
JP7071959B2 (en) * | 2016-08-12 | 2022-05-19 | エフ.ホフマン-ラ ロシュ アーゲー | Sulfonylpyridyl TRP inhibitor |
MX2019002612A (en) | 2016-09-07 | 2019-08-21 | Pharmakea Inc | Uses of a lysyl oxidase-like 2 inhibitor. |
MA46204A (en) | 2016-09-07 | 2021-03-17 | Pharmakea Inc | CRYSTALLINE FORMS OF LYSYL OXIDASE TYPE 2 INHIBITOR AND METHODS FOR MANUFACTURING THEM |
GEP20247634B (en) | 2016-12-09 | 2024-06-25 | Vertex Pharma | Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
EP3554500A1 (en) | 2016-12-16 | 2019-10-23 | Galderma Research & Development | Trpa1 antagonists for use in the treatment of atopic dermatitis |
WO2018130437A1 (en) | 2017-01-10 | 2018-07-19 | Bayer Aktiengesellschaft | Heterocyclene derivatives as pest control agents |
WO2018167113A1 (en) | 2017-03-16 | 2018-09-20 | F. Hoffmann-La Roche Ag | New bicyclic compounds as atx inhibitors |
BR112019019017A2 (en) | 2017-03-16 | 2020-04-14 | Hoffmann La Roche | heterocyclic compounds useful as dual atx / ca inhibitors |
NZ760052A (en) | 2017-06-08 | 2024-07-05 | Vertex Pharma | Methods of treatment for cystic fibrosis |
US11517564B2 (en) | 2017-07-17 | 2022-12-06 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
TWI799435B (en) | 2017-08-02 | 2023-04-21 | 美商維泰克斯製藥公司 | Processes for preparing compounds |
IL273831B2 (en) | 2017-10-19 | 2024-10-01 | Vertex Pharma | Crystalline forms and compositions of cftr modulators |
EP3720849A2 (en) * | 2017-12-08 | 2020-10-14 | Vertex Pharmaceuticals Incorporated | Processes for making modulators of cystic fibrosis transmembrane conductance regulator |
TWI810243B (en) | 2018-02-05 | 2023-08-01 | 美商維泰克斯製藥公司 | Pharmaceutical compositions for treating cystic fibrosis |
WO2019164778A1 (en) | 2018-02-20 | 2019-08-29 | Genentech, Inc. | Process for preparing 1-arylsulfonyl-pyrrolidine-2-carboxamide transient receptor potential channel antagonist compounds and crystalline forms thereof |
US10710994B2 (en) | 2018-03-19 | 2020-07-14 | Genentech, Inc. | Oxadiazole transient receptor potential channel inhibitors |
WO2019200246A1 (en) | 2018-04-13 | 2019-10-17 | Alexander Russell Abela | Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
EP3892617A4 (en) | 2018-12-07 | 2022-08-31 | Unimatec Co., Ltd. | Fluorinated pyrimidine compound and production method therefor |
CN110156834A (en) * | 2019-06-05 | 2019-08-23 | 镇江市高等专科学校 | A kind of yellow fluorescence copper (I) complex and its preparation method and application |
FR3114235A1 (en) | 2020-09-18 | 2022-03-25 | Université Grenoble Alpes | INHIBITION OF ASTROCYTIC TRPA1 CHANNEL AS A NEW NEUROPROTECTIVE THERAPEUTIC TARGET IN THE PRODROMAL PHASES OF ALZHEIMER'S DISEASE |
CN116600787A (en) * | 2020-11-19 | 2023-08-15 | 阿库西亚医疗有限责任公司 | Nonaqueous gel composition |
IT202100015098A1 (en) | 2021-06-09 | 2022-12-09 | Flonext S R L | TRPA1 CHANNEL ANTAGONIST COMPOUND FOR USE IN DEGENERATIVE DISEASES OF THE RETINA |
WO2023133502A1 (en) * | 2022-01-07 | 2023-07-13 | The Johns Hopkins University | Treatment and prevention of trigeminal neuralgia |
WO2024146945A1 (en) | 2023-01-07 | 2024-07-11 | Syngenta Crop Protection Ag | Novel carboxamide and sulfonamide pesticidal compounds |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8614201B2 (en) * | 2009-06-05 | 2013-12-24 | Janssen Pharmaceutica Nv | Heterocyclic amides as modulators of TRPA1 |
EP2520566A1 (en) * | 2011-05-06 | 2012-11-07 | Orion Corporation | New Pharmaceutical Compounds |
CN104203236A (en) * | 2012-01-17 | 2014-12-10 | 味之素株式会社 | Heterocyclic amide derivative and pharmaceutical product containing same |
WO2014098098A1 (en) | 2012-12-18 | 2014-06-26 | 味の素株式会社 | Heterocyclic amide derivative, and medicine containing same |
WO2014113671A1 (en) * | 2013-01-18 | 2014-07-24 | Cubist Pharmaceuticals, Inc. | Inhibiting the transient receptor potential a1 ion channel |
US9394308B2 (en) * | 2013-01-18 | 2016-07-19 | Merck Sharp & Dohme Corp. | Inhibiting the transient receptor potential A1 ion channel |
JP2016532673A (en) * | 2013-10-11 | 2016-10-20 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Substituted heterocyclic sulfonamide compounds useful as TRPA1 modulators |
KR20160135183A (en) * | 2014-01-28 | 2016-11-25 | 이에이 파마 가부시키가이샤 | Heterocyclic sulfonamide derivative and medicine comprising same |
-
2016
- 2016-02-12 JP JP2017542390A patent/JP6700291B2/en active Active
- 2016-02-12 EP EP16703990.8A patent/EP3256463B1/en active Active
- 2016-02-12 BR BR112017017052-3A patent/BR112017017052A2/en not_active IP Right Cessation
- 2016-02-12 US US15/042,310 patent/US10179782B2/en active Active
- 2016-02-12 MX MX2017010300A patent/MX2017010300A/en unknown
- 2016-02-12 AU AU2016217851A patent/AU2016217851A1/en not_active Abandoned
- 2016-02-12 PT PT167039908T patent/PT3256463T/en unknown
- 2016-02-12 SG SG11201706451TA patent/SG11201706451TA/en unknown
- 2016-02-12 CA CA2975196A patent/CA2975196A1/en not_active Abandoned
- 2016-02-12 PE PE2017001378A patent/PE20180177A1/en unknown
- 2016-02-12 CN CN201680009724.XA patent/CN107922392B/en active Active
- 2016-02-12 WO PCT/EP2016/052950 patent/WO2016128529A1/en active Application Filing
- 2016-02-12 KR KR1020177025946A patent/KR20170118166A/en unknown
- 2016-02-12 EA EA201791836A patent/EA033497B1/en not_active IP Right Cessation
- 2016-02-12 CR CR20170367A patent/CR20170367A/en unknown
- 2016-02-15 TW TW105104384A patent/TW201639829A/en unknown
-
2017
- 2017-07-13 IL IL253478A patent/IL253478A0/en unknown
- 2017-07-28 CO CONC2017/0007679A patent/CO2017007679A2/en unknown
- 2017-08-03 CL CL2017001987A patent/CL2017001987A1/en unknown
- 2017-08-15 PH PH12017501478A patent/PH12017501478A1/en unknown
-
2018
- 2018-08-31 HK HK18111222.7A patent/HK1251815A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
HK1251815A1 (en) | 2019-03-29 |
JP6700291B2 (en) | 2020-05-27 |
PH12017501478A1 (en) | 2018-01-29 |
EA201791836A1 (en) | 2017-12-29 |
TW201639829A (en) | 2016-11-16 |
PE20180177A1 (en) | 2018-01-22 |
KR20170118166A (en) | 2017-10-24 |
IL253478A0 (en) | 2017-09-28 |
EP3256463B1 (en) | 2019-10-09 |
EA033497B1 (en) | 2019-10-31 |
CN107922392A (en) | 2018-04-17 |
BR112017017052A2 (en) | 2018-04-10 |
US20160264567A1 (en) | 2016-09-15 |
CR20170367A (en) | 2017-09-12 |
WO2016128529A1 (en) | 2016-08-18 |
CN107922392B (en) | 2020-07-21 |
AU2016217851A1 (en) | 2017-08-03 |
SG11201706451TA (en) | 2017-09-28 |
PT3256463T (en) | 2019-12-05 |
CA2975196A1 (en) | 2016-08-18 |
JP2018513107A (en) | 2018-05-24 |
US10179782B2 (en) | 2019-01-15 |
EP3256463A1 (en) | 2017-12-20 |
MX2017010300A (en) | 2017-12-04 |
CL2017001987A1 (en) | 2018-08-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2017007679A2 (en) | Derivatives of 1- (het) arylsulfonyl- (pyrrolidine or piperidine) -2-carboxamide and their use as trpa1 antagonists | |
CO2018012171A2 (en) | Heteroaryl substituted pyridines and methods of use | |
DOP2018000270A (en) | NEW PIPERIDINYL DERIVATIVES, A PROCESS FOR THE PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
ECSP16005566A (en) | SULFONAMIDES AS SODIUM CHANNEL MODULATORS | |
CR10356A (en) | DERIVATIVES OF 4-BENZILPHTHALAZINONA 2-SUBSTITUTED AS HISTAMINE ANTAGONISTS H1 AND H3 | |
NI201600018A (en) | PYRROLAMIDE DERIVATIVES SUBSTITUTED WITH GLIOXAMIDE AND THEIR USE AS MEDICINES FOR THE TREATMENT OF HEPATITIS B. | |
CR20160518A (en) | COMPOUNDS TO TREAT SPINAL MUSCLE ATROPHY | |
CR20150045A (en) | HEPATITIS C INHIBITORS | |
BR112015004111A2 (en) | new bicyclic derivatives | |
BR112015022804A2 (en) | new octahidro-pyrrol [3,4-c] -pyrrol derivatives and their analogues as autotaxin inhibitors | |
BR112012010186B8 (en) | heteroaryl derivatives containing n as jak3 kinase inhibitors and pharmaceutical composition comprising them | |
NI201400005A (en) | INDAZOLES | |
PE20151423A1 (en) | TETRAHYDROPYRANIL DERIVATIVES INHIBITORS OF HCV | |
CO7131360A2 (en) | Novel substituted cyclic n-pyridinyl amides as kinase inhibitors | |
CR20200276A (en) | SULFAMOYLARYLAMIDES AND THEIR USE AS MEDICINES FOR THE TREATMENT OF HEPATITIS B (DIVISIONAL EXP. 2015-0059) | |
DOP2018000062A (en) | PIRIDINONA DICABOXAMIDS FOR USE AS BROMODOMINUM INHIBITORS | |
UY30938A1 (en) | NICOTINAMIDE DERIVATIVES, SALTS AND PHARMACEUTICALLY ACCEPTABLE SOLVATES, COMPOSITIONS AND APPLICATIONS. | |
UY33655A (en) | CCR30 CO-CRYSTALS AND SALES OF INHIBITORS | |
ECSP16079730A (en) | 2-AMINO-6-METHYL-4,4a, 5,6-TETRAHYDROPYRAN [3,4-d] [1,3] THIAZIN-8a (8H) -YL-1,3-THIAZOL-4-ILAMIDES | |
CU24248B1 (en) | DERIVATIVES OF (PIPERIDIN-4-IL) PIPERAZINA-1-CARBOXAMIDE / CARBOXYLATE AS ANTAGONIST OF THE RECEIVER-H3 | |
PE20151669A1 (en) | AZETIDINYLOXPHENYLPYRROLIDINE COMPOUNDS | |
EA201791396A1 (en) | DERIVATIVES OF IMIDAZOPIRIDAZIN AS PI3Kβ INHIBITORS | |
EA201791397A1 (en) | HYDROCYCLILES RELATED IMIDAZOPIRIDAZIN DERIVATIVES AS PI3Kβ INHIBITORS | |
UY32333A (en) | QUATERNARY DERIVATIVES OF PIRIDINE AND USE OF THE SAME | |
CU20130037A7 (en) | NEW DIHYDROBENZOXATIAZEPIN DERIVATIVES, THEIR PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |